ISSN: 0976-7126
Yabo *et al.*, 15(8):12-15, 2024

International Journal of Pharmacy & Life Sciences
Open Access to Researcher

Innovations in Malaria Prevention and Treatment

Sadiq Hussaini Yabo[1]*, Himani Tiwari[2] and Kaushal Kishor Chandrul[3]

1, Student of B. Pharm. 4th Year; 2, HOD; 3, Principal

Department of Pharmacy, Mewar University, Gangrar Chittorgarh, (R.J.) - India

Article info

Received: 05/07/2024

Revised: 23/07/2024

Accepted: 01/08/2024

© IJPLS

www.ijplsjournal.com

Abstract

Malaria is a significant infectious disease caused by five species of single-celled Plasmodium parasites, primarily Plasmodium falciparum and Plasmodium vivax, transmitted through the bites of Anopheles mosquitoes. This disease continues to pose a grave threat to nearly half of the global population, with the majority of its victims being young children in Africa. In 2015 alone, hundreds of thousands of people succumbed to malaria. The management of malaria involves a combination of vector control techniques, such as the use of insecticide-treated bed nets and indoor residual spraying, alongside medications for both treatment and prevention. Artemisinin-based combination therapies (ACTs) have played a crucial role in reducing malaria-related mortality rates significantly. However, the emergence and spread of drug-resistant strains threaten these gains.

Advances in our understanding of the molecular basis of malaria have facilitated the development of new diagnostics, drugs, and insecticides. Current research focuses on novel combination therapies that target drug-resistant parasites and innovative strategies, including vaccines and new vector control methods. Despite these advances, eradicating malaria requires a coordinated international effort across multiple fronts.

Key words: Anopheles, Antimalarials, Malaria, Plasmodium, Drug resistance, Epidemiology, Mass drug administration, Vaccine

Introduction

Malaria is an infectious disease that affects humans and other animals, transmitted by the bite of infected mosquitoes. Frequent symptoms of malaria include fever, exhaustion, nausea, and headaches. In severe cases, it can lead to more serious conditions such as coma, jaundice, convulsions, and even death. Typically, symptoms appear 10-15 days after being bitten by an infected mosquito. If treatment is not administered or is inadequate, the disease can relapse months later. Individuals who survive malaria may experience less severe symptoms if they contract the disease again. Plasmodium parasites are the causative agents of malaria, and they are transmitted exclusively through the bites of Anopheles mosquitoes. Once injected into the bloodstream, these parasites travel to the liver, where they mature and multiply.

There are five species of Plasmodium that infect humans: Plasmodium falciparum, P. vivax, P. malariae, P. ovalecurtisi, and P. ovalewallikeri. Among these, P. falciparum is the most deadly, responsible for the majority of malaria-related deaths.

***Corresponding Author**

Diagnostic methods for malaria include rapid antigen-based tests and microscopic examination of blood smears. Polymerase chain reaction (PCR) tests are also available but are not widely used due to their cost and complexity. Preventive measures include avoiding mosquito bites through the use of bed nets, insect repellents, and mosquito control strategies. For travelers to malaria-endemic regions, various prophylactic treatments are recommended. Vaccines are currently under development, with some showing promise in reducing the risk of malaria.

Signs and Symptoms

Adults infected with malaria often experience symptoms such as headaches, fatigue, abdominal pain, and muscle aches, in addition to periodic episodes of fever. In children, common symptoms include fever, cough, vomiting, and diarrhea. Initial symptoms can mimic those of the flu, leading to potential misdiagnosis. Other symptoms may include hemolyticanemia, jaundice, seizures, and the characteristic cycle of chills, fever, and sweating. Symptoms usually begin 10 to 15 days after infection, although some strains of P. vivax can cause delayed onset. Travelers who have taken malaria prophylaxis may develop symptoms after discontinuing the medication. Severe malaria is typically caused by P. falciparum, which can lead to complications such as cerebral malaria, severe anemia, and multi-organ failure.

Causes

Malaria is caused by infection with Plasmodium parasites, with P. falciparum and P. vivax being the most prevalent and dangerous. P. falciparum is the most lethal, causing the highest number of malaria-related deaths, while P. vivax is more widespread outside of Africa. Other species of Plasmodium that infect humans include P. malariae, P. ovalecurtisi, P. ovalewallikeri, and P. knowlesi, which is zoonotic, meaning it can be transmitted from animals to humans. The transmission of malaria occurs through the bite of an infected Anopheles mosquito. Once bitten, the parasites are injected into the bloodstream and migrate to the liver, where they mature and multiply. After maturing, the parasites re-enter the bloodstream and infect red blood cells, leading to the symptoms associated with malaria.

Diagnosis

Diagnosing malaria involves a combination of clinical assessment and laboratory testing. The World Health Organization (WHO) recommends that malaria should be suspected in any individual presenting with fever in an endemic area. Diagnostic confirmation is achieved through rapid diagnostic tests (RDTs) or microscopic examination of blood smears. RDTs detect specific antigens produced by malaria parasites and provide results within 15-30 minutes. Microscopy, considered the gold standard for malaria diagnosis, involves examining a blood smear under a microscope to identify the presence of parasites. This method is highly accurate but requires skilled personnel and proper laboratory facilities. In addition to RDTs and microscopy, PCR tests can be used to detect malaria parasites, though their use is limited due to cost and complexity. Early and accurate diagnosis is crucial for effective treatment and control of malaria.

Prevention

Preventing malaria involves a multi-faceted approach that includes the use of medications, mosquito control measures, and personal protection strategies. The use of insecticide-treated bed nets (ITNs) has proven to be one of the most effective preventive measures, significantly reducing the incidence of malaria. Indoor residual spraying (IRS) with insecticides is another key strategy, targeting mosquitoes that rest on indoor surfaces. Preventive medications, or chemoprophylaxis, are recommended for travelers to malaria-endemic regions and for certain high-risk populations. These medications include drugs such as atovaquone-proguanil, doxycycline, and mefloquine, which are taken before, during, and after exposure to malaria. Additionally, the development of malaria vaccines has shown promise. The RTSS vaccine, the first to be licensed, has demonstrated efficacy in reducing malaria incidence among children in endemic areas. However, the ultimate goal of malaria prevention is eradication, which requires a comprehensive approach to reduce human and mosquito populations and transmission rates.

Treatment

Malaria treatment depends on the type of Plasmodium species and the severity of the disease. For uncomplicated malaria, oral antimalarial medications are used, with artemisinin-based combination therapies (ACTs) being the most effective. ACTs combine two or more drugs with different mechanisms of action to reduce the risk of resistance and improve treatment outcomes. In cases of severe malaria, typically caused by P. falciparum, intravenous antimalarial drugs and supportive care are necessary. These severe cases often require treatment in an intensive care unit. The timely administration of effective antimalarial drugs can significantly reduce mortality rates, especially in children. However, the overuse of antimalarial drugs can lead to resistance and inadequate treatment of other febrile illnesses. Rapid diagnostic tests help ensure appropriate use of antimalarials by confirming malaria infection before treatment.

Conclusion

Malaria continues to be a major global health challenge, particularly in sub-Saharan Africa, where it causes significant morbidity and mortality. Despite substantial progress in reducing malaria incidence and mortality rates through the use of insecticide-treated nets, indoor residual spraying, and effective antimalarial drugs, the disease remains a threat due to emerging drug resistance and the challenges of maintaining and expanding control measures.

The future of malaria control and eradication depends on sustained international efforts, including the development of new tools such as vaccines and innovative vector control strategies. Additionally, addressing the social and environmental determinants of malaria transmission, such as poverty and inadequate healthcare infrastructure, is crucial for achieving long-term success. With continued research, funding, and collaboration, it is possible to envision a world free of malaria.

Reference

1. Malaria, R. B. (2005). World malaria report 2005. *World Health Organization and UNICEF*.
2. White, N. J. (1996). The treatment of malaria. *New England journal of medicine*, *335*(11), 800-806.
3. Tuteja, R. (2007). Malaria− an overview. *The FEBS journal*, *274*(18), 4670-4679.
4. Talapko, J., Škrlec, I., Alebić, T., Jukić, M., & Včev, A. (2019). Malaria: the past and the present. *Microorganisms*, *7*(6), 179.
5. Cowman, A. F., Healer, J., Marapana, D., & Marsh, K. (2016). Malaria: biology and disease. *Cell*, *167*(3), 610-624.

Cite this article as:
Yabo S.H., Tiwari H. and Chandrul K.K. (2024). Innovations in Malaria Prevention and Treatment.

Int. J. of Pharm. & Life Sci., 15(8): 12-15.

Source of Support: Nil
Conflict of Interest: Not declared
For reprints contact: ijplsjournal@gmail.com